GEORGE CHOLANKERIL to Disease Progression
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Disease Progression.
Connection Strength
0.108
-
Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
Score: 0.023
-
Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers. Ann Hepatol. 2019 Sep - Oct; 18(5):679-684.
Score: 0.018
-
Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 02; 31(2):149-156.
Score: 0.018
-
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017 Dec 21; 23(47):8263-8276.
Score: 0.017
-
Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017 Oct; 112(10):1495-1505.
Score: 0.016
-
Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Hepatology. 2017 07; 66(1):46-56.
Score: 0.016